Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Summary

Gossamer Bio submitted a New Drug Application to the FDA for seralutinib for the treatment of pulmonary arterial hypertension. The submission represents a significant regulatory milestone for the company's lead candidate.